Background: Frequent reuse of syringes during medical injections is fuelling HIV and HCV epidemics in many low-and middle-income countries including Pakistan.
Introduction
Syringe reuse during therapeutic injections has contributed to the global epidemics of Hepatitis C (1,2) and HIV (3) (4) (5) (6) , and is well-documented in high income (7, 8) and low-and middle-income countries (9) (10) (11) . In Pakistan, high reuse of syringes during therapeutic injections (13) has led to a national prevalence of Hepatitis C of 4.8% (12) , with some districts as high as 12%, and has contributed to at least one community outbreak of HIV (14) . Therapeutic injections in Pakistan range from 4.2-4.6 injections per person annually (13) , with 17-50% of these injections being given with reused syringes (12, 13, 15, 16) . Currently, "conventional disposable syringes" are used in Pakistan. Punjab government introduced reuse-prevention syringes (RUP) in its health facilities in 2017 (17). WHO's injection safety guidelines recommend RUP for all injections and sharp-injury protection (SIP) syringes, wherever feasible (18) .
We had previously compared and demonstrated that the total national supply of syringes in Pakistan was sufficient to meet the demand for the approximately 1.1 billion syringes used annually for immunisation, diabetes, laboratory testing and for medicines in clinics or hospitals (13) ; therefore reuse of syringes cannot be attributed merely on national shortfall of syringes as had been previously thought. However, such national aggregates hide reuse by individual practitioners. This study explored the extent and pattern of such reuse. The study also explored a novel methodology to identify reuse to avoid providers' self-promotion and patients' recall biases as well as paradigms behind injection demand and supply in the communities.
Methods
Rawalpindi and Tando Allah Yar were identified in collaboration with the Ministry of Health, Pakistan -as districts exemplifying high and low human development indices (19) to understand injection reuse practices across the extremes of human development. Rawalpindi city is a large metropolis with a large number of public and private, primary, secondary and tertiary medical care centres and specialists. Although around half of the population of Rawalpindi district is rural, the villages are close to the city. Tando Allah Yar is completely rural and poor.
In the first phase, all healthcare providers from all 19 union councils of Tando Allah Yar and 38 (1:5) randomly selected union councils from Rawalpindi were listed. Thus, 6053 providers were identified as any individual who sees patients in communities, irrespective of their training or licensure. This list was used to construct a simple randomisation-sampling frame to recruit healthcare providers. The study was powered for type I error (α): 0.05 and type II (β): 0.2; giving total of 320 providers to be divided between districts (Epi Info®). The relative number of the providers between districts was weighted for the providers per union councils included in listing giving 174 providers from Rawalpindi and 145 from Tando Allah Yar. At each healthcare provider's facility, two patients were approached to participate in a brief survey, from among those present at the time of study team visit and based on who was encountered first.
Provider and patient questionnaire were pre-tested to ensure validity and appropriateness. Providers' questionnaire asked about their training and practice pattern. Patients' questionnaire asked about their demographics and healthcare seeking behaviours. Both were asked about knowledge about syringe reuse and its harm.
Reuse of injections was identified by 3 measures: 1) the study teams observed providers while managing patients including while giving injections; 2) recognising that such observations may be subject to a Hawthorne effect (20, 21) where providers' behaviour may change when they recognise that they are being observed, we also asked patients if they felt that the injection they received was given with a new or reused syringe; and 3) since many patients may not know whether a syringe was reused, we also used a proxy measure. We asked providers how many syringes they stocked for the previous day and compared these against the number of injections they said they had provided yesterday. This difference would identify providers that were sure to reuse syringes since they would have insufficient syringes for all the injections they gave. This established a minimum level of reuse since providers can potentially reuse even when they have insufficient syringes. Recall bias was limited by asking only about the previous day. Variables were compared using SPSS+ v20. Proportions (of those that give injections), reusers were compared using chi square tests. Predictors of reuse of syringes were explored using linear regression with predictors described in Table 5 .
The study was reviewed and approved by the Ethical Review Committee of Bridge Consultants Foundation. Informed consent was obtained from all subjects.
Results
We interviewed 319 providers (145 from Tando Allah Yar and 174 from Rawalpindi). Their mean age was 45 years (SD: 11.8) in Rawalpindi and 39.6 years (SD: 10.2) in Tando Allah Yar and 83% were men. Half of all providers from Rawalpindi and a quarter from Tando Allah Yar were doctors with more urban than rural providers being doctors ( Table 1 ) Patients from Tando Allah Yar were more likely to be farmers, labourers or housewives, while those from Rawalpindi were mostly skilled labourers, housewives, office workers or students ( Table 2 ) .
Commonest reasons for medical visits were fever, influenza-like symptoms or body (51% of visits) or abdominal pain, vomiting or diarrhoea (11% of visits). An injection was provided during 52% patient visits in Rawalpindi and during 90% in Tando Allah Yar. Patients from Rawalpindi reported having received a median of 3 injections during the previous year compared to 8 injections by patients from Tando Allah Yar.
Patients from Tando Allah Yar also report around 3.8 (SD: 2.5) visits to a healthcare provider by a member of their household during the previous month compared to 2.5 (SD: 5.7) by those from Rawalpindi. During all such visits, an injection was given. Overall, 351 (56%) of patients felt that an injection was necessary. Such perceptions were higher in Tando Allah Yar than in Rawalpindi (79% vs. 38%, P < 0.001) ( Table 2 ) . Providers reciprocated such perceptions in that 46-72% of providers felt that an injection was required for common ailments such as fever, influenza, body aches or diarrhoea (  Table 4 ).
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In practice, it was highly likely that an injection would be given for fever (OR: 7.9, P = 0.022) but not for abdominal pain/ diarrhoea (OR 5.4, P = 0.187).
Providers from Rawalpindi charge around US$ 1.44 (SD: 1.42) for a visit when no injection was given and US$ 1.51 (SD: 1.87) if an injection was provided; there were no rural urban differences. Providers from Tando Allah Yar charged US$ 0.59 (0.62) when an injection was provided and US$ 0.62 (SD: 0.48) when not provided. Providers charged US$ 0.56 (SD: 0.57) in rural and US$ 0.69 (SD: 0.30) in urban locales. Providers from Rawalpindi reported giving a mean of 8.8 (SD: 9.6) intramuscular injections, 3.5 (SD: 3.7) intravenous injections and 2.3 (SD: 3.9) intravenous drip daily. Providers from Tando Allah Yar give 10.0 (SD: 9.6) intramuscular injections. We asked providers how many syringes had they stocked for the day. 140 (48%) providers from Rawalpindi and 122 (46%) from Tando Allah Yar gave more injections than their daily stock of syringes. and therefore would be very likely to reuse syringes regularly. For analysis, these are labelled as "likely re-users". No urban provider from Rawalpindi fell into this category, while urban and rural providers in Tando Allah Yar were very similar ( Table 3 ) . Around 38% of all providers were likely to reuse consistently. These "likely re-users" give around 14 injections daily compared to 12 by those who are less likely to re-use syringes. Since re-users stock around 5 syringes a day, they would likely reuse syringes for 9 injections in any given day (  Table 4 ).
Of the variables used in the linear regression model, only practicing in Tando Allah Yar (AOR 1.92, range 1.9-7.69) and a longer duration of practice (AOR 0.6% for each year in practice, range 0.1-1%) increased the likelihood for reuse. Physicians were just as likely to reuse as non-physicians. Our teams observed patient encounters for any injection reuse and we also asked patients if they had observed syringe reuse. Both of these modes of inquiry identified reuse during <5% of observations/ visits. Nearly all providers, but few patients, were aware of the possibility of acquiring injection site injuries or infections such as hepatitis or HIV from reused syringes.
Discussion
We found that around half of the patients had received an injection during their current visit and that at least 38% of the providers were likely to reuse syringes during injections. Reuse happens just as often by physicians or non-physicians and is irrespective of sex of providers or the fee charged. Both providers and patients felt that injections were necessary for common ailments.
The high injection demand and provision seen in our study is consistent with prior experience from Pakistan (21) or the region (13, (23) (24) (25) (26) (27) . Patients expect to receive injections for minor ailments such as fever or influenza-like symptoms and willingly pay for these, on the mistaken belief in the efficacy of injections to overcome common symptoms that eventually abate with time (10) . Healthcare providers comply with such wishes and are convinced of the necessity of injections. This belief is common among providers irrespective of whether they are likely or not to reuse syringes.
Syringe reuse happens against a backdrop of frequent injections. Around 38% procure too few syringes for the injections they provide and will likely reuse consistently. They also see more patients and give more injections. They charge slightly less per visit than providers that do not reuse; however, their fees remain largely the same whether they give an injection or not. These providers stock a median of 5 syringes and give 14 injections daily; meaning that each syringe is reused 2-3 times. Provider's knowledge of potential harms of reuse and their incentives to reuse also mean that approaches such as information provision or availability of auto-disable syringes will not work unless these are the only type of syringes available. Additionally, simply demanding or making laws against reuse are not likely to succeed. On the other hand, since providers' savings from syringe reuse are hidden from the patients, there may be a potential role for a patient-focused approach where patients are made more aware of syringe reuse and its harm (28) .
Community approaches that reduce information asymmetry between providers and patients have been promising (29) . One intervention in Tando Allah Yar, Pakistan, improved patient awareness from 15% to 29% within 6 months (30). Other complements may be to use branding of providers that visibly do not reuse syringes as "safe providers". Another option would be use positive deviance inquiry in communities to reduce injection demand and for syringe reuse (31-33).
Limitations
A limitation of our study is that since we compared the supply of syringes vs. injections given, we can only estimate the minimum reuse by providers. In reality, a provider may reuse more often, although perhaps not by much since they would then adjust their syringe procurement accordingly in the long run.
Conclusion
Our study highlighted the high prevalence of syringe reuse during therapeutic injections in communities and suggests that patient-centred approaches (demand reduction and increased awareness of the harm of syringe reuse), but probably not provider-centred approaches, may help reduce syringe reuse. New research should explore why patients seek such unnecessary care and test behavioural approaches such as cognitive behavioural therapy, expectation management or whether patients will pay for safe injections, to make medical practice and injections safer in poor communities.
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